Prelude Therapeutics And AbCellera Enter Partnership To Develop First-In-Class Precision Antibody Drug Conjugates In Oncology
Portfolio Pulse from Benzinga Newsdesk
Prelude Therapeutics Incorporated (NASDAQ:PRLD) and AbCellera (NASDAQ:ABCL) have announced a multi-year partnership to discover, develop, and commercialize potentially first-in-class treatments for cancer patients. The collaboration will combine Prelude's expertise in targeted protein degradation, medicinal chemistry, and clinical development with AbCellera's antibody discovery and development engine to generate novel precision antibody drug conjugates (ADCs).
November 01, 2023 | 9:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbCellera has entered into a partnership with Prelude Therapeutics to develop novel cancer treatments. This could potentially lead to the development of first-in-class treatments, which could significantly boost AbCellera's market position and revenues.
The partnership with Prelude Therapeutics could potentially lead to the development of first-in-class treatments, which could significantly boost AbCellera's market position and revenues. This is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Prelude Therapeutics has entered into a partnership with AbCellera to develop novel cancer treatments. This could potentially lead to the development of first-in-class treatments, which could significantly boost Prelude's market position and revenues.
The partnership with AbCellera could potentially lead to the development of first-in-class treatments, which could significantly boost Prelude's market position and revenues. This is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100